524708-03-0

524708-03-0 structure

Name: APE1 Inhibitor III
Chemical Name: N-(3-(benzo[d]thiazol-2-yl)-6-isopropyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl)acetamide
CAS Number: 524708-03-0
Molecular Formula: C₁₉H₂₁N₃OS₂
Molecular Weight: 371.52000
Catalog: Signaling Pathways Cell Cycle/DNA Damage DNA/RNA Synthesis
Create Date: 2017-06-27 14:12:43
Modify Date: 2024-01-04 14:43:57
APE1-IN-1 is a potent and blood-brain barrier (BBB) penetrant apurinic/apyrimidinic (AP) endonuclease 1 (APE1) inhibitor with an IC50 value of 2 μM. APE1-IN-1 can potentiate the cytotoxicity of the alkylating agents Methylmethane sulfonate and Temozolomide (HY-17364) to cancer cells[1].

Name	N-(3-(benzo[d]thiazol-2-yl)-6-isopropyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl)acetamide
Synonyms	N-(3-Benzo[d]thiazol-2-yl-6-isopropyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl)acetamide APE1 Inhibitor III

Description	APE1-IN-1 is a potent and blood-brain barrier (BBB) penetrant apurinic/apyrimidinic (AP) endonuclease 1 (APE1) inhibitor with an IC50 value of 2 μM. APE1-IN-1 can potentiate the cytotoxicity of the alkylating agents Methylmethane sulfonate and Temozolomide (HY-17364) to cancer cells[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> DNA/RNA Synthesis
Target	IC50: 2 μM (APE1)[1]
In Vitro	APE1-IN-1 (compound 3) exhibits an IC50 of 2 μM in the qHTS assay and an IC50 of 12 μM in a radiotracer incision assay (RIA)[1]. APE1-IN-1 (0, 1, 3, 10, 30, or 100 μM; 15 min) inhibits HeLa whole cell extract AP site incision in a dose-dependent manner[1]. APE1-IN-1 (5-30 μM; 24 h) exhibits cytotoxic activity against HeLa cells, and potentiates the activity of methyl methansulfonate and Temozolomide (HY-17364)[1]. Cell Cytotoxicity Assay[1] Cell Line: HeLa cells Concentration: 5-30 μM Incubation Time: 24 h Result: Exhibited cytotoxic activity against HeLa cells with a 50% reduction in cell viability occurring at ~15 μM. Greatly potentiated the activity of methyl methansulfonate (0.4 mM) and Temozolomide (HY-17364) (1 mM) with optimal synergy occurring at ~5 μM and ~10 μM, respectively.
In Vivo	APE1-IN-1 (30 mpk; IP; single dosage) exhibits favorable pharmacokinetic property[1]. Pharmacokinetic Parameters of APE1-IN-1 (compound 3) (IP; 30 mpk) in CD1 mice[1]. Plasma Brain t1/2 (h) 2.1 1 brain/plasma 21 Cmax (μM) 16 217 tmax (h) 0.25 0.25 CLogP 2.83 Animal Model: CD1 male mice (n = 3)[1] Dosage: 30 mpk Administration: IP; single dosage Result: Showed lipophilic (CLogP = 2.8), crossed the BBB quite readily, giving rise to a B/P ratio of 21.
References	[1]. Rai G, et al. Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors. J Med Chem. 2012 Apr 12;55(7):3101-12.

Molecular Formula	C₁₉H₂₁N₃OS₂
Molecular Weight	371.52000
Exact Mass	371.11300
PSA	101.71000
LogP	4.76060

524708-03-0	2710375-18-9
927827-98-3	29936-81-0
1188890-30-3	88191-84-8
133335-36-1	403848-57-7
1186648-22-5	443798-55-8
1158522-08-7	940364-43-2
134104-43-1	131615-57-1
6906-52-1	930439-75-1
1018584-77-4	1375289-11-4
849349-65-1	127437-46-1